KLF13 restrains Dll4-muscular Notch2 axis to improve the muscle atrophy.

Shu YangLijiao XiongGuangyan YangJiaqing XiangLixing LiLin KangZhen Liang

Published in: Journal of cachexia, sarcopenia and muscle (2024)

This study sheds new light on the mechanisms underlying skeletal muscle atrophy and potential drug targets. KLF13 regulates muscle atrophy and is a potential therapeutic target. Clofoctol is an attractive compound for repurposing studies to treat skeletal muscle atrophy.

Keyphrases

skeletal muscle
insulin resistance
transcription factor
emergency department
cell proliferation
type diabetes
metabolic syndrome
adverse drug
climate change
body composition